New combo therapy aims to stop rare organ disease

This phase 3 trial tests whether adding the experimental drug SCTC21C to standard chemotherapy (bortezomib, cyclophosphamide, dexamethasone) works better than chemo alone for people newly diagnosed with AL amyloidosis. The study will enroll 90 participants and measure how well the treatment clears abnormal proteins from the blood and delays organ damage. The goal is to find a more effective way to control this rare disease.